Education
About Us
Working with TipRanks
Follow Us
Infant Bacterial Therapeutics (DE:9IB)
:9IB
9IB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.78 - €10.95
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€57.48M
Enterprise Value€225.47M
Total Cash (Recent Filing)€191.76M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Aug 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding13,018,137
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-6.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Infant Bacterial Therapeutics AB News
PremiumCompany Announcements
IBT to Present Phase III Trial Results at ESPGHAN 2025
PremiumCompany Announcements
Infant Bacterial Therapeutics AGM Highlights Strategic Resolutions
PremiumCompany Announcements
IBT Advances FDA Submission for Key Drug Candidate
PremiumCompany Announcements
Infant Bacterial Therapeutics AB Gains FDA Breakthrough Status for IBP-94149IB FAQ
What was Infant Bacterial Therapeutics’s price range in the past 12 months?
Infant Bacterial Therapeutics lowest stock price was €2.78 and its highest was €10.95 in the past 12 months.
What is Infant Bacterial Therapeutics’s market cap?
Infant Bacterial Therapeutics’s market cap is €57.48M.
When is Infant Bacterial Therapeutics’s upcoming earnings report date?
Infant Bacterial Therapeutics’s upcoming earnings report date is Aug 20, 2025 which is in 36 days.
How were Infant Bacterial Therapeutics’s earnings last quarter?
Currently, no data Available
Is Infant Bacterial Therapeutics overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics’s price is currently Overvalued.
Does Infant Bacterial Therapeutics pay dividends?
Infant Bacterial Therapeutics does not currently pay dividends.
What is Infant Bacterial Therapeutics’s EPS estimate?
Infant Bacterial Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Infant Bacterial Therapeutics have?
Infant Bacterial Therapeutics has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics?
Currently, no hedge funds are holding shares in DE:9IB
Company Description
Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
Technical Analysis
SynAct Pharma AB
―
Saniona AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―
Cantargia AB
―